Terms: = Testicular cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
41 results:
1. Genomic landscape and distinct molecular subtypes of primary testicular lymphoma.
Zhang W; Yang P; Yang Y; Liu S; Xu Y; Wu C; Wang J; Liu C; Liu H; Li S; Huang W; Jing H
J Transl Med; 2024 May; 22(1):414. PubMed ID: 38693538
[TBL] [Abstract] [Full Text] [Related]
2. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
3. Frequent expression of CD45RO memory T cell marker as well as low to high expression of PD-1 and pd-l1 inhibitory molecules in seminoma and dysgerminoma.
Farahani H; Dehghanian AR; Khademolhosseini A; Haghshenas MR; Erfani N
J Reprod Immunol; 2024 Feb; 161():104184. PubMed ID: 38171036
[TBL] [Abstract] [Full Text] [Related]
4. [Diagnosis and treatment of malignant mesothelioma of the tunica vaginalis testis: a series of 7 cases].
Huang KB; Cao Y; Yao K; Zhou FJ; Liu ZW; Li XD
Zhonghua Wai Ke Za Zhi; 2023 Sep; 61(9):812-817. PubMed ID: 37491176
[No Abstract] [Full Text] [Related]
5. Primary testicular lymphoma demonstrates overexpression of the Wilms tumor 1 gene and different mRNA and miRNA expression profiles compared to nodal diffuse large B-cell lymphoma.
Mansoor A; Akhter A; Shabani-Rad MT; Deschenes J; Yilmaz A; Trpkov K; Stewart D
Hematol Oncol; 2023 Dec; 41(5):828-837. PubMed ID: 37291944
[TBL] [Abstract] [Full Text] [Related]
6. TAMs pd-l1(+) in the reprogramming of germ cell tumors of the testis.
Melotti S; Ambrosi F; Franceschini T; Giunchi F; Filippo GD; Franchini E; Massari F; Mollica V; Tateo V; Bianchi FM; Colecchia M; Acosta AM; Lobo J; Fiorentino M; Ricci C
Pathol Res Pract; 2023 Jul; 247():154540. PubMed ID: 37209574
[TBL] [Abstract] [Full Text] [Related]
7. TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies.
Meng J; Gao J; Li X; Gao R; Lu X; Zhou J; Yan F; Wang H; Liu Y; Hao Z; Zhang X; Liang C
Cell Oncol (Dordr); 2023 Jun; 46(3):745-759. PubMed ID: 36823338
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies.
Giampietri C; Scatozza F; Crecca E; Vigiano Benedetti V; Natali PG; Facchiano A
J Transl Med; 2022 Oct; 20(1):467. PubMed ID: 36224560
[TBL] [Abstract] [Full Text] [Related]
9. Metachronous testicular Metastases from Merkel Cell Carcinoma (MCC): A Case Report and Literature Review.
Laffi A; Cozzi G; Spada F; Fazio N; Bertuzzi AF; Santoro A
Am J Case Rep; 2022 Aug; 23():e936552. PubMed ID: 36031755
[TBL] [Abstract] [Full Text] [Related]
10. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of cancers: A Pan-cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract] [Full Text] [Related]
11. Pan-cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract] [Full Text] [Related]
12. CX-072 (pacmilimab), a Probody pd-l1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
Sanborn RE; Hamid O; de Vries EG; Ott PA; Garcia-Corbacho J; Boni V; Bendell J; Autio KA; Cho DC; Plummer R; Stroh M; Lu L; Thistlethwaite F
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301808
[TBL] [Abstract] [Full Text] [Related]
13. Expression of programmed death ligand-1 (pd-l1) in metastatic and postchemotherapy viable testicular germ cell tumors.
Al-Hogbani M; Duguay J; Wagner DC; Haferkamp A; Joubert P; Frees S; Rendon R; Power N; Périgny M; Toren P
Urol Oncol; 2021 May; 39(5):303.e1-303.e8. PubMed ID: 33685799
[TBL] [Abstract] [Full Text] [Related]
14. Penile Lymphoepithelioma-Like Carcinoma: A Rare Case With pd-l1 Expression.
Machado-Neves R; Teixeira B; Fonseca E; Valente P; Lindoro J; Vila F; Polónia A
Int J Surg Pathol; 2021 Sep; 29(6):690-692. PubMed ID: 33455515
[TBL] [Abstract] [Full Text] [Related]
15. Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center.
Ji YS; Park SH
Cancer Res Treat; 2021 Jul; 53(3):874-880. PubMed ID: 33285049
[TBL] [Abstract] [Full Text] [Related]
16. Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies.
Sardana R; Mishra SK; Williamson SR; Mohanty A; Mohanty SK
Semin Oncol; 2020 Dec; 47(6):367-379. PubMed ID: 33160642
[TBL] [Abstract] [Full Text] [Related]
17. The immunotherapy revolution in genitourinary malignancies.
U Gandhy S; Madan RA; Aragon-Ching JB
Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.
Zhu MMT; Burugu S; Gao D; Yu J; Kos Z; Leung S; Horst BA; Nielsen TO
Mod Pathol; 2020 Sep; 33(9):1753-1763. PubMed ID: 32350416
[TBL] [Abstract] [Full Text] [Related]
19. PD1/pd-l1 Axis in Uro-oncology.
Junker K; Eckstein M; Fiorentino M; Montironi R
Curr Drug Targets; 2020; 21(13):1293-1300. PubMed ID: 32213156
[TBL] [Abstract] [Full Text] [Related]
20. Differences in pd-l1-Expressing Macrophages and Immune Microenvironment in testicular Germ Cell Tumors.
Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P
Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108
[TBL] [Abstract] [Full Text] [Related]
[Next]
